World Investment Advisors Acquires 4,181 Shares of DexCom, Inc. (NASDAQ:DXCM)

World Investment Advisors lifted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,174 shares of the medical device company's stock after purchasing an additional 4,181 shares during the quarter. World Investment Advisors' holdings in DexCom were worth $2,607,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in DXCM. IFM Investors Pty Ltd lifted its position in DexCom by 8.9% in the 1st quarter. IFM Investors Pty Ltd now owns 80,794 shares of the medical device company's stock valued at $5,416,000 after acquiring an additional 6,601 shares in the last quarter. GF Fund Management CO. LTD. lifted its position in DexCom by 1.6% in the 1st quarter. GF Fund Management CO. LTD. now owns 84,374 shares of the medical device company's stock valued at $5,762,000 after acquiring an additional 1,305 shares in the last quarter. OneDigital Investment Advisors LLC lifted its position in DexCom by 6.3% in the 1st quarter. OneDigital Investment Advisors LLC now owns 64,070 shares of the medical device company's stock valued at $4,375,000 after acquiring an additional 3,798 shares in the last quarter. Fisher Funds Management LTD lifted its position in DexCom by 32.7% in the 1st quarter. Fisher Funds Management LTD now owns 1,647,333 shares of the medical device company's stock valued at $112,496,000 after acquiring an additional 405,612 shares in the last quarter. Finally, Silver Oak Securities Incorporated bought a new position in DexCom in the 1st quarter valued at approximately $456,000. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

DXCM stock traded up $0.68 during trading on Wednesday, reaching $84.44. The company's stock had a trading volume of 899,651 shares, compared to its average volume of 4,398,608. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $117.19. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $33.11 billion, a P/E ratio of 63.00, a price-to-earnings-growth ratio of 1.77 and a beta of 1.44. The company's fifty day moving average is $83.74 and its 200-day moving average is $79.90.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.32 EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Nicholas Augustinos sold 3,672 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director owned 33,411 shares in the company, valued at $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on DXCM. Wall Street Zen cut DexCom from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Canaccord Genuity Group increased their price target on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Robert W. Baird lowered their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Mizuho began coverage on DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, DexCom currently has an average rating of "Moderate Buy" and an average target price of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.